These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22825352)

  • 1. HDL- cholesterol: a nut too hard to crack?
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352
    [No Abstract]   [Full Text] [Related]  

  • 2. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?
    Ahmed MH
    Diabetes Technol Ther; 2008 Aug; 10(4):328-9. PubMed ID: 18715207
    [No Abstract]   [Full Text] [Related]  

  • 3. HDL cholesterol and atherosclerosis.
    Mazzone T
    Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020
    [No Abstract]   [Full Text] [Related]  

  • 4. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 5. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 7. [HDL level or HDL function as the primary target in preventive cardiology].
    Schaefer JR
    Herz; 2012 Feb; 37(1):51-5. PubMed ID: 22258137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 9. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
    Taylor J
    Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754
    [No Abstract]   [Full Text] [Related]  

  • 10. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
    Duriez P
    Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843
    [No Abstract]   [Full Text] [Related]  

  • 11. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL: back to the drawing board.
    Johns Hopkins Med Lett Health After 50; 2007 May; 19(3):1-2. PubMed ID: 17657883
    [No Abstract]   [Full Text] [Related]  

  • 13. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 14. Where now for new drugs for atherosclerosis?
    Opar A
    Nat Rev Drug Discov; 2007 May; 6(5):334-5. PubMed ID: 17539053
    [No Abstract]   [Full Text] [Related]  

  • 15. CETP Inhibition: does the future look promising?
    Toth PP
    Curr Cardiol Rep; 2011 Dec; 13(6):559-65. PubMed ID: 21909703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.
    Harv Heart Lett; 2007 Mar; 17(7):1-2. PubMed ID: 17378073
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CETP inhibitors to increase HDL cholesterol levels.
    Tall AR
    N Engl J Med; 2007 Mar; 356(13):1364-6. PubMed ID: 17387130
    [No Abstract]   [Full Text] [Related]  

  • 19. Will CETP inhibition survive the demise of torcetrapib?
    Olsson AG
    Curr Atheroscler Rep; 2008 Apr; 10(2):97-9. PubMed ID: 18417061
    [No Abstract]   [Full Text] [Related]  

  • 20. HDL-cholesterol levels and cardiovascular risk: acCETPing the context.
    Lange RA; Lindsey ML
    Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.